PRINCETON, N.J., Aug. 5 /PRNewswire/ -- Signum Biosciences, Inc. today announced the appointment of Dr. Braham Shroot, formerly CSO of Barrier Therapeutics, as Chief Executive Officer. Dr. Shroot replaces Dr.

Barrier Therapeutics, Inc. (NASDAQ: BTRX) announced today the introduction of Xolegel CorePak(TM) for the treatment of seborrheic dermatitis. Now, patients with this chronic skin condition need only one prescription to get quick itch relief and to safely manage the overall condition long term.

PRINCETON, N.J., June 17 /PRNewswire-FirstCall/ -- Barrier Therapeutics, Inc. , a pharmaceutical company that develops and markets dermatology products, today published its first annual Vusion Baby Bottom Line Report that includes results from a nationwide survey of new and expectant mothers.

PRINCETON, N.J., April 9, 2008 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc.

PRINCETON, N.J., Feb. 1, 2008 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc.